Home » Improving outcomes for colitis patients: the HALT-Colitis trial » Improving outcomes for colitis patients: the HALT-Colitis trial

Improving outcomes for colitis patients: the HALT-Colitis trial

Patient sat on sofa at home and holding stomach whilst looking at laptop screen

Status: Ongoing

In this trial we will randomise patients at diagnosis to either just simple first line treatment (5 aminosalicylic acid-5ASA) or 5ASA with Faecal Microbial Transplantation (FMT). This work builds on STOP-Colitis, our previous pilot FMT study in ulcerative colitis.

Project aims

The primary aim of this trial is to see if ‘correction’ of a damaged microbiome can prevent the need for patients to escalate to advance immunomodulatory treatments.

Research projects

Dentistry research and teaching biorepository

The dentistry research and teaching biorepository (DRTB) is a collection of human tissue and other…

Next generation probiotics: Developing microbial-based oral formulations…

There are trillions of bacteria living within our bowels. This is normal as…

Advancing research in IBD: the SLICC inception…

Since 2021 and in collaboration with Hofmann La Roche we have set up…